文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Li S H, Kobayashi Y, Yamauchi Y, Gonda T, Tsunematsu T

Department of Pharmacology, Shimane Medical University, Izumo, Japan.

Clin Exp Pharmacol Physiol. 1996 Mar;23(3):236-40. doi: 10.1111/j.1440-1681.1996.tb02602.x.

The effects of a formula of traditional Chinese medicine, TBL-1, on collagen-induced arthritis (CIA) were investigated in DBA/1J mice. 2. From 4 weeks after the first immunization with bovine type II collagen (CII), TBL-1 or indomethacin was administered orally for 13 weeks. 3. Clinical scores of CIA were decreased by both TBL-1 and indomethacin intervention compared with the control CII-immunized group. 4. Radiographic scores of phalangeal destruction were markedly improved by TBL-1 intervention (P < 0.001), but indomethacin failed. 5. The suppressive effects of TBL-1, but not indomethacin, were manifested in reduced serum anti-CII antibody titres (P < 0.001). 6. These findings suggest that TBL-1 may play a role in regulating some immune responses in the present arthritis model.

在DBA/1J小鼠中研究了一种中药配方TBL-1对胶原诱导性关节炎（CIA）的影响。2. 自首次用牛II型胶原（CII）免疫后4周起，口服给予TBL-1或吲哚美辛，持续13周。3. 与对照CII免疫组相比，TBL-1和吲哚美辛干预均降低了CIA的临床评分。4. TBL-1干预显著改善了指骨破坏的放射学评分（P < 0.001），但吲哚美辛未起作用。5. TBL-1具有抑制作用，可降低血清抗CII抗体滴度（P < 0.001），而吲哚美辛无此作用。6. 这些发现表明，TBL-1可能在当前关节炎模型中调节某些免疫反应中发挥作用。

Li S H, Kobayashi Y, Yamauchi Y, Gonda T, Tsunematsu T

Department of Pharmacology, Shimane Medical University, Izumo, Japan.

Clin Exp Pharmacol Physiol. 1996 Mar;23(3):236-40. doi: 10.1111/j.1440-1681.1996.tb02602.x.

The effects of a formula of traditional Chinese medicine, TBL-1, on collagen-induced arthritis (CIA) were investigated in DBA/1J mice. 2. From 4 weeks after the first immunization with bovine type II collagen (CII), TBL-1 or indomethacin was administered orally for 13 weeks. 3. Clinical scores of CIA were decreased by both TBL-1 and indomethacin intervention compared with the control CII-immunized group. 4. Radiographic scores of phalangeal destruction were markedly improved by TBL-1 intervention (P < 0.001), but indomethacin failed. 5. The suppressive effects of TBL-1, but not indomethacin, were manifested in reduced serum anti-CII antibody titres (P < 0.001). 6. These findings suggest that TBL-1 may play a role in regulating some immune responses in the present arthritis model.

在DBA/1J小鼠中研究了一种中药配方TBL-1对胶原诱导性关节炎（CIA）的影响。2. 自首次用牛II型胶原（CII）免疫后4周起，口服给予TBL-1或吲哚美辛，持续13周。3. 与对照CII免疫组相比，TBL-1和吲哚美辛干预均降低了CIA的临床评分。4. TBL-1干预显著改善了指骨破坏的放射学评分（P < 0.001），但吲哚美辛未起作用。5. TBL-1具有抑制作用，可降低血清抗CII抗体滴度（P < 0.001），而吲哚美辛无此作用。6. 这些发现表明，TBL-1可能在当前关节炎模型中调节某些免疫反应中发挥作用。